Skip to main content
Deborah Frincke, one of the nation’s preeminent computer scientists and cybersecurity experts, serves as associate laboratory director of ORNL’s National Security Science Directorate. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Deborah Frincke, one of the nation’s preeminent computer scientists and cybersecurity experts, serves as associate laboratory director of ORNL’s National Security Science Directorate. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Sergei Kalinin

Sergei Kalinin, a scientist and inventor at the Department of Energy’s Oak Ridge National Laboratory, has been elected a fellow of the Microscopy Society of America professional society.

Brenda Smith, shown here working with a gas viscometer in her research lab, is one of several people concurrently researching the thermophysical properties of feedstock gas. Their research will support computational researchers who are designing processes to separate isotopes. Credit: Carlos Jones/ORNL, US Dept. of Energy

For years Brenda Smith found fulfillment working with nuclear batteries, a topic she’s been researching as a chemist at Oak Ridge National Laboratory.

ORNL’s Sergei Kalinin and Rama Vasudevan (foreground) use scanning probe microscopy to study bulk ferroelectricity and surface electrochemistry -- and generate a lot of data. Credit: Jason Richards/ORNL, U.S. Dept. of Energy

At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.

Oak Ridge National Laboratory’s MENNDL AI software system can design thousands of neural networks in a matter of hours. One example uses a driving simulator to evaluate a network’s ability to perceive objects under various lighting conditions. Credit: ORNL, U.S. Dept. of Energy

The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.

Ken Andersen

From Denmark to Japan, the UK, France, and Sweden, physicist Ken Andersen has worked at neutron sources around the world. With significant contributions to neutron scattering and the scientific community, he’s now serving in his most important role yet.

Parans Paranthaman, a researcher in the Chemical Sciences Division at ORNL, coordinated research efforts to study the filter efficiency of the N95 material. His published results represent one of the first studies on polypropylene as it relates to COVID-19. Credit: ORNL/U.S. Dept. of Energy

When COVID-19 was declared a pandemic in March 2020, Oak Ridge National Laboratory’s Parans Paranthaman suddenly found himself working from home like millions of others.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.

Data from the ORNL Free Air CO2 Enrichment experiment were combined with observations from more than 100 other FACE sites for this analysis, which revealed new insights about the relationship between plant biomass growth and soil carbon storage. Credit: Jeff Warren/ORNL, U.S. Dept. of Energy

Oak Ridge National Laboratory was among an international team, led by Lawrence Livermore National Laboratory, who synthesized 108 elevated carbon dioxide, or CO2, experiments performed in various ecosystems to find out how much carbon is

Neutron scattering experiments show electric charges, shown in red, blue and grey, in the SARS-CoV-2 main protease site where telaprevir binds to the structure. The experiments provide critical data for the design of small-molecule drugs to treat COVID-19. Credit: Jill Hemman and Michelle Lehman/ORNL, U.S. Dept. of Energy

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.